Akkaraju Srinivas's Form 4 filing
Mineralys Therapeutics, Inc. (MLYS) · filed Feb 16, 2023
- Accession no.
- 0001628280-23-003923
- Filed
- Feb 16, 2023, 4:54 PM ET
- Trade date
- Feb 14, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $15.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Akkaraju SrinivasCIK 0001253170 | Director, 10% Owner |
| Samsara BioCapital, L.P.CIK 0001699737 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2023 | Common Stock | CConversionAcquired | +3,581,861 | –F1 | – | 3,581,861 | Indirect | |
| Feb 14, 2023 | Common Stock | PPurchaseAcquired | +937,500 | $16.00 | +$15,000,000 | 4,519,361 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2023 | Common Stock | CConversionDisposed | −2,135,504 | $0.00 | $0 | 0 | Indirect | |
| Feb 14, 2023 | Common Stock | CConversionDisposed | −1,446,357 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.
Referenced by the price of 1 transaction in Table I.